Phase II trial of single agent carboplatin followed by dose-intense paclitaxel, followed by maintenance paclitaxel therapy in stage IV ovarian, fallopian tube, and peritoneal cancers: A Southwest Oncology Group trial

Gynecologic Oncology

Volumn 88, Issue 3, 2003, Pages 282-288

  Markman, Maurie ^a   Glass, Tracy ^b   Smith, Harriet O ^c   Hatch, Kenneth D ^d   Weiss, Geoffrey R ^e   Taylor, Sarah A ^f   Goodwin, J Wendall ^g   Alberts, David S ^d  

^a LERNER RESEARCH INSTITUTE   (United States)

^b SW Oncology Group Statistical Center ^*  (United States)

^c UNIVERSITY OF NEW MEXICO   (United States)

^d UNIVERSITY OF ARIZONA   (United States)

^e UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^f UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^g Ozarks Regional Community Clinical Oncology Program   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; PACLITAXEL;

ADULT; AGED; ANTIGEN DETECTION; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG FATALITY; DRUG MEGADOSE; FEMALE; HISTOPATHOLOGY; HUMAN; INTESTINE OBSTRUCTION; KIDNEY DYSFUNCTION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; MULTICENTER STUDY; NEUROTOXICITY; NEUTROPENIA; OVARY CARCINOMA; PERITONEUM CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; UTERINE TUBE CARCINOMA;

EID: 0037340966     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-8258(02)00100-2     Document Type: Article

References (19)

1. McGuire WP, Hoskins WJ, Brady MF, Brady MF, B.S., Kucera PR, Partridge EE, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6.
2. Piccart M.J., Bertelsen K., James K., Cassidy J., Mangioni C., Simonsen E., et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer three-year results . J Natl Cancer Inst. 92:2000;699-708.
3. Ozols R.F., Bundy B.N., Fowler J., Clarke-Pearson D., Mannel R., Hartenbach E.M., Baergen R. Randomized phase III study of cisplatin (CIS)/paclitaxel (PAC) versus carboplatin (CARBO)/PAC in optimal stage III epithelial ovarian cancer (OC) a Gynecologic Oncology Group Trial (GOG 158) . Proc Am Soc Clin Oncol. 18:1999;356a. (Abstract).
4. du Bois A., Lueck H.J., Meier W., Moebus V., Costa S.D., Bauknecht T., et al. Cisplatin/paclitaxel vs carboplatin/paclitaxel in ovarian cancer update of an Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group trial . Proc Am Soc Clin Oncol. 18:1999;356a. (Abstract).
5. Neijt J.P., Engelholm S.A., Tuxen M.K., Sorensen P.G., Hansen M., Sessa C., et al. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol. 18:2000;3084-3182.
6. Bonadonna G., Zambetti M., Valagussa P. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results. J Am Med Assoc. 273:1995;542-547.
7. Norton L., Simon R. The Norton-Simon hypothesis revisited. Cancer Teat Rep. 70:1986;163-169.
8. Bast R.C. Jr, Klug T.L., St. John E., Jenison E., Niloff J.M., Lazarus H., et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 309:1983;883-887.
9. Rustin G.J.S., Nelstrop A.E., Bentzen S.M., Bond S.J., McClean P. Selection of active drugs for ovarian cancer based on CA-125 and standard response rates in phase II trials. J Clin Oncol. 18:2000;1733-1739.
10. Rowinsky E.K., Donehower R.C. Paclitaxel (Taxol). N Engl J Med. 332:1995;1004-1014.
11. Markman M., Hakes T., Barakat R., Curtin J., Almadrones L., Hoskins W. Follow-up of Memorial Sloan-Kettering Cancer Center patients treated on National Cancer Institute Treatment Referral Center Protocol 9103 paclitaxel in refractory ovarian cancer . J Clin Oncol. 14:1996;796-799.
12. Calvert A.H., Newell D.R., Gumbrell L.A., O'Reilly S., Burnell M., Boxall F.E., et al. Carboplatin dosage prospective evaluation of a simple formula based on renal function . J Clin Oncol. 17:1989;1748-1756.
13. Muggia F.M., Braly P.S., Brady M.F., Sutton G., Niemann T.H., Lentz S.L., et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer a Gynecologic Oncology Group study . J Clin Oncol. 18:2000;106-115.
14. Rohl J., Kushner D., Markman M. Chronic administration of single-agent paclitaxel in gynecologic malignancies. Gynecol Oncol. 81:2001;201-205.
15. Markman M., Bundy B.N., Alberts D.S., Fowler J.M., Clark-Pearson D.L., Carson L.F., et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma an Intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group and Eastern Cooperative Oncology Group . J Clin Oncol. 19:2001;1001-1007.
16. Eisenhauer E.A., ten Bokkel Huinink W.W., Swenerton K.D., Gianni L., Myles J., van der Burg M.E.L., et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer high-dose versus low-dose and long versus short infusion . J Clin Oncol. 12:1994;2654-2666.
17. Markman M., Liu P.Y., Wilczynski S., Monk B.J., Copeland L., Alberts D. Phase 3 randomized trial of 12 versus 3 months of single-agent paclitaxel in patients with advanced ovarian cancer who attained a clinically defined complete response to platinum/paclitaxel-based chemotherapy. A Southwest Oncology Group and Gynecologic Oncology Group trial. Gynecol Oncol. 84:2002;479. (Abstract).
18. Markman M., Hall J., Spitz D., Weiner S., Carson L., Van Le L., Baker M. Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer. J Clin Oncol. 20:2002;2365-2369.
19. Browder T., Butterfield C.E., Kraling B.M., Shi B., Marshall B., O'Reilly M.S., Folkman J. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 60:2000;1878-1886.